X

Drug Profile

IMVT 1402

Alternative Names: HL 161 ANS; IMVT-1402

Latest Information Update: 13 Aug 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator HanAll Biopharma
Class Monoclonal antibodies
Mechanism of Action Neonatal Fc receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Autoimmune disorders

Most Recent Events

08 Aug 2024 Immunovant plans to initiate a potentially registrational program in Myasthenia gravis for IMVT 1402 by March 31st 2025
06 Aug 2024 Immunovant plans to keep 3 IND applications active for multiple indications
06 Aug 2024 Immunovant plans a registrational program for IMVT-1402 for Chronic inflammatory demyelinating polyneuropathy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com